HealthcareServices

Global Carcinoid Tumor Market Set for Strong Expansion, Reaching $2.88 Billion With 10.1% CAGR by 2030

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the carcinoid tumor market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Carcinoid Tumor Market’s size between 2026 and 2030?

The carcinoid tumor market size has expanded swiftly over recent years. It is anticipated to increase from $1.77 billion in 2025 to $1.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. The expansion witnessed during the historic period can be linked to enhanced awareness of rare cancers, the development of oncology care facilities, the presence of somatostatin analog therapies, the proliferation of cancer specialty clinics, and breakthroughs in neuroendocrine tumor research.

The carcinoid tumor market size is projected to experience swift expansion in the coming years, anticipated to reach $2.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. Factors driving this growth during the projected timeframe include the increasing creation of new targeted treatments, higher spending on research for rare cancer therapies, the broader application of precision oncology strategies, a growing preference for individualized treatment plans, and a greater emphasis on patient quality-of-life results. Key trends foreseen for this period encompass the increased acceptance of targeted neuroendocrine tumor treatments, a rise in the application of combination drug therapies, an intensified focus on diagnosing tumors earlier, the proliferation of specialized oncology treatment facilities, and a stronger commitment to long-term disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

Which Drivers Are Shaping Strategic Decisions In The Carcinoid Tumor Market?

The expansion of the obese population is anticipated to fuel the progress of the carcinoid tumor market in the future. The obese population comprises individuals with a body mass index (BMI) of 30 or greater, signifying an excess of body fat. This rise in the obese population stems from factors such as unhealthy eating patterns, insufficient physical activity, inactive lifestyles, and increased intake of processed, high-calorie foods. Obesity contributes to the development of carcinoid tumors by fostering chronic inflammation, insulin resistance, and heightened secretion of growth factors that support tumor proliferation. For example, in May 2025, the Office for Health Improvement and Disparities (OHID), a UK-governmentagency, reported that in 2023–2024, approximately 64.5% of adults (18+) in England were either overweight or living with obesity, marking a slight increase from 64.0% in the preceding period (2022–2023). Consequently, the increasing obese population is propelling the growth of the carcinoid tumor market.

What Segment Classifications Make Up The Carcinoid Tumor Market?

The carcinoid tumor market covered in this report is segmented –

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types

2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End User: Hospital And Clinics, Academic Institutions, Research Organizations

Subsegments:

1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors

2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma

3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors

4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

How Are Emerging Trends Affecting The Progression Of The Carcinoid Tumor Market?

Leading companies in the carcinoid tumor market are concentrating on advancements in diagnostic technologies, such as the fully automated chromogranin A test, to improve early detection and enhance treatment outcomes. The automated chromogranin A (CgA) test is a completely automated diagnostic tool used to measure levels of chromogranin A, a biomarker commonly associated with neuroendocrine tumors, including carcinoid tumors. For example, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, obtained FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This represents the first FDA-approved Chromogranin A (CgA) test and the only automated immunoassay globally for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Designed to quantify CgA concentration in human serum, the assay enables laboratories and cancer centers to track tumor growth and evaluate treatment efficacy. By replacing manual laboratory-developed tests, it boosts lab efficiency and ensures clearer result interpretation. The test operates on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, utilizing TRACE technology to deliver precise results in under 30 minutes.

Which Leading Companies Dominate The Carcinoid Tumor Market Share?

Major companies operating in the carcinoid tumor market are Novartis AG, Ipsen SA, Pfizer Inc, Merck & Co Inc, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc, Takeda Pharmaceutical Company, Bayer AG, Exelixis Inc, Lexicon Pharmaceuticals Inc, HUTCHMED, Crinetics Pharmaceuticals, Clovis Oncology, Taiho Pharmaceutical, Eisai Co Ltd, Teva Pharmaceutical Industries

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

How Does The Carcinoid Tumor Market Perform Across Major Global Regions?

North America was the largest region in the carcinoid tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Carcinoid Tumor Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp

Browse Through More Reports Similar to the Global Carcinoid Tumor Market 2026, By The Business Research Company

Desmoid Tumors Market Report 2026

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Carcinoembryonic Antigen Market Report 2026

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Basal Cell Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795